Emerging Cancer Therapies: Vaccines, Gene Editing, and Beyond

Although a definitive cure for cancer remains elusive, researchers are rapidly advancing innovative treatments—such as therapeutic vaccines, gene‑editing techniques, and engineered immune cells—that could transform future care.

Understanding the distinction between a cure and remission is essential:

• Cure. All detectable cancer cells are eradicated and the disease is not expected to recur.
• Remission. Cancer is reduced to few or no detectable cells. Remission comes in two forms:
  • Complete remission: No cancer can be found, typically within the first five years after therapy.
  • Partial remission: Tumors shrink, but residual cancer cells remain detectable.

Even after complete remission, microscopic cancer cells may persist, leaving a risk of relapse.

Many of these newer modalities are used alongside—or as alternatives to—standard chemotherapy and radiation.

Cancer immunotherapy empowers the immune system to recognize and destroy malignant cells. Because tumors often hide from immune surveillance, several strategies have been devised to expose them.

Therapeutic Vaccines

Only two cancer vaccines have FDA approval today, but a growing pipeline aims to train the immune system against tumor‑specific antigens. Researchers are testing next‑generation vaccines—sometimes in combination with established drugs—to improve response rates (see 2021 review).

CAR T‑Cell Therapy

Chimeric antigen receptor (CAR) T‑cell therapy removes a patient’s T‑cells, engineers them to express a tumor‑targeting receptor, and reinfuses them to seek out cancer. FDA‑approved products include:

• Tisagenlecleucel (Kymriah)
• Axicabtagene ciloleucel (Yescarta)
• Brexucabtagene autoleucel (Tecartus)
• Lisocabtagene maraleucel (Breyanzi)
• Idecabtagene vicleucel (Abecma)
• Ciltacabtagene autoleucel (Carvykti)

These agents are approved for several blood cancers—leukemias, lymphomas, and multiple myeloma. While often life‑saving, CAR T can trigger serious toxicities such as cytokine release syndrome; clinicians mitigate these with agents like tocilizumab. Ongoing trials are exploring CAR T for solid tumors, which present delivery challenges.

Monoclonal Antibodies

Monoclonal antibody (mAb) therapy generates large quantities of lab‑crafted antibodies that bind cancer‑cell antigens, flagging them for destruction. Key FDA‑approved mAbs include:

• Alemtuzumab (Campath) – targets CD52 on malignant B‑ and T‑cells.
• Trastuzumab (Herceptin) – blocks HER2 signaling in HER2‑positive breast cancer.
• Blinatumomab (Blincyto) – a bispecific T‑cell engager that links CD19 on leukemia cells to CD3 on T‑cells.

Some antibodies are conjugated to radioactive isotopes or chemotherapy drugs, delivering lethal payloads directly to tumor cells. Examples:

• Ibritumomab tiuxetan (Zevalin) – radio‑labeled for non‑Hodgkin lymphoma.
• Trastuzumab emtansine (Kadcyla) – links trastuzumab to the cytotoxic agent DM1 for HER2‑positive breast cancer.

Immune Checkpoint Inhibitors

Checkpoint inhibitors block proteins (e.g., PD‑1, CTLA‑4) that normally dampen T‑cell activity, thereby unleashing a stronger anti‑tumor response. They are standard of care for many lung, skin, kidney and other cancers.

Gene Therapy & Gene Editing

Gene‑based approaches aim to correct or replace defective genetic instructions that drive tumor growth. Early‑stage clinical trials are testing viral vectors and CRISPR‑based edits to modify patient T‑cells or directly target tumor DNA.

CRISPR‑edited T‑cells have shown stable gene modification for up to nine months in small 2020 phase‑1 studies of refractory cancers, with no serious adverse events reported.

Oncolytic Virotherapy

Oncolytic viruses selectively infect and lyse cancer cells, releasing tumor antigens to stimulate immunity. Talimogene laherparepvec (T‑VEC), an engineered herpesvirus, is FDA‑approved for unresectable melanoma. Hundreds of trials (2020‑2023 reviews) are evaluating a variety of oncolytic platforms, especially adenovirus‑based constructs, in melanoma, gastrointestinal and other malignancies.

Hormone‑Based Therapies

For cancers driven by hormones—such as breast or prostate cancer—agents that block hormone production or receptor signaling can slow tumor progression.

Nanoparticle Delivery Systems

Nanoparticles, particles smaller than a cell, improve the solubility, stability and tumor targeting of chemotherapeutics. FDA‑approved nanomedicines include:

• Abraxane (albumin‑bound paclitaxel)
• Doxil (liposomal doxorubicin)

Numerous investigational nanoparticle formulations are listed on the U.S. National Library of Medicine’s Clinical Trials portal, many of which combine with immunotherapies to boost efficacy.

In summary, while no universal cure exists yet, a growing arsenal of immunotherapies, gene‑editing tools, virotherapies and nanotechnologies is expanding options for patients and offering hope for durable remissions.